Learn more

COMPASS THERAPEUTICS LLC

Overview
  • Total Patents
    66
  • GoodIP Patent Rank
    22,127
  • Filing trend
    ⇧ 228.0%
About

COMPASS THERAPEUTICS LLC has a total of 66 patent applications. It increased the IP activity by 228.0%. Its first patent ever was published in 2016. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are F STAR DELTA LTD, GILLIES STEPHEN D and MEDITOPE BIOSCIENCES INC.

Patent filings per year

Chart showing COMPASS THERAPEUTICS LLCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Schmidt Michael March 37
#2 Bobrowicz Piotr 35
#3 Eskiocak Ugur 29
#4 Widboom Paul 22
#5 Sabzevari Helen 19
#6 Schuetz Thomas Joseph 18
#7 Lajoie Jason M 17
#8 Leung Cheuk Lun 17
#9 Tighe Iii Robert V 17
#10 Metenou Simon 17

Latest patents

Publication Filing date Title
WO2020205504A1 Common light chains and methods of use
WO2020150496A1 Formulations of antibodies that bind human cd137 and uses thereof
WO2020132557A1 Transgenic mouse expressing common human light chain
WO2020102387A1 Multispecific binding constructs against checkpoint molecules and uses thereof
WO2020033925A2 Antibodies that bind cd277 and uses thereof
WO2020033926A2 Antibodies that bind cd277 and uses thereof
WO2020033923A1 Antigen binding agents that bind cd277 and uses thereof
WO2019226658A1 Multispecific antigen-binding compositions and methods of use
EP3797120A1 Compositions and methods for enhancing the killing of target cells by nk cells
WO2019199896A1 Agonist antibodies against human cd137 in cancer that express mhc i
US2020308293A1 Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019089753A2 Cd137 antibodies and pd-1 antagonists and uses thereof
CN111182951A Filtration and chromatography pods and methods of using the same
CA3069438A1 Agonist antibodies that bind human cd137 and uses thereof
CN109562162A Multispecific immune modulability antigen-binding constructs
AU2016322934A1 Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
BR112017015136A2 multispecific immunomodulator antigen binding construct polypeptide, multispecific immunomodulator antigen binding construct, conjugate, pharmaceutical composition, method for treating an individual with cancer, method for inhibiting or reducing cancer growth, composition, cell, method of making a polypeptide of multispecific immunomodulatory antigen binding construct, vector or vector set and kit